- Home
- INSM vs PAYC Comparison
INSM vs PAYC Comparison
Compare INSM & PAYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- PAYC
- Stock Information
- Founded
- INSM 1988
- PAYC 1998
- Country
- INSM United States
- PAYC United States
- Employees
- INSM N/A
- PAYC N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- PAYC Computer Software: Prepackaged Software
- Sector
- INSM Health Care
- PAYC Technology
- Exchange
- INSM Nasdaq
- PAYC Nasdaq
- Market Cap
- INSM 12.6B
- PAYC 13.1B
- IPO Year
- INSM 2000
- PAYC 2014
- Fundamental
- Price
- INSM $65.08
- PAYC $252.38
- Analyst Decision
- INSM Strong Buy
- PAYC Hold
- Analyst Count
- INSM 16
- PAYC 11
- Target Price
- INSM $95.36
- PAYC $228.50
- AVG Volume (30 Days)
- INSM 2.5M
- PAYC 523.8K
- Earning Date
- INSM 05-08-2025
- PAYC 05-07-2025
- Dividend Yield
- INSM N/A
- PAYC 0.59%
- EPS Growth
- INSM N/A
- PAYC N/A
- EPS
- INSM N/A
- PAYC 7.02
- Revenue
- INSM $381,030,000.00
- PAYC $1,913,800,000.00
- Revenue This Year
- INSM $30.36
- PAYC $9.65
- Revenue Next Year
- INSM $115.55
- PAYC $9.59
- P/E Ratio
- INSM N/A
- PAYC $36.03
- Revenue Growth
- INSM 20.77
- PAYC 9.87
- 52 Week Low
- INSM $21.92
- PAYC $139.50
- 52 Week High
- INSM $84.91
- PAYC $254.48
- Technical
- Relative Strength Index (RSI)
- INSM 35.80
- PAYC 73.82
- Support Level
- INSM $63.81
- PAYC $223.36
- Resistance Level
- INSM $73.39
- PAYC $231.40
- Average True Range (ATR)
- INSM 2.53
- PAYC 6.99
- MACD
- INSM -0.38
- PAYC 2.76
- Stochastic Oscillator
- INSM 13.26
- PAYC 94.21
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About PAYC Paycom Software Inc.
Paycom is a fast-growing provider of payroll and human capital management software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 19,500 clients as of 2023, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.